Modality
Cell Therapy
MOA
TYK2i
Target
BCL-2
Pathway
RNA Splicing
MDSSchizophrenia
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
Oct 2019
→ Dec 2025
Phase 2Current
NCT04421411
178 pts·Schizophrenia
2019-10→2025-12·Recruiting
NCT05906311
1,043 pts·MDS
2023-02→2025-06·Terminated
1,221 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-0310mo agoPh2 Data· MDS
2025-12-283mo agoPh2 Data· Schizophrenia
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Recruit…
P2
Termina…
Catalysts
Ph2 Data
2025-06-03 · 10mo ago
MDS
Ph2 Data
2025-12-28 · 3mo ago
Schizophrenia
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04421411 | Phase 2 | Schizophrenia | Recruiting | 178 | EFS |
| NCT05906311 | Phase 2 | MDS | Terminated | 1043 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Olpainavolisib | Moderna | Phase 1 | Menin |